Related Experiment Video
Updated: Jan 23, 2026

A Rat Orthotopic Renal Transplantation Model for Renal Allograft Rejection
Published on: February 2, 2022
Thinking Outside the Box: Managing Refractory Antibody-Mediated Rejection Based on Injury-Related Phenotype to
Rajeev Sharma1, Abhinav Seth1, Briana Sowers1
1Transplant Surgery, West Virginia University, Morgantown, WV, USA.
Abstract:
We present the case of a patient with end-stage renal disease secondary to type 2 diabetes mellitus and hypertension who developed refractory chronic active antibody-mediated rejection following renal transplantation. Despite standard of care treatment, including intravenous immunoglobulin, therapeutic plasma exchange, and steroids, the patient exhibited persistent donor-specific antibodies and renal allograft injury. Given elevated interleukin-6 levels, tocilizumab, an IL-6 receptor monoclonal antibody, was started with marked improvement in serum creatinine, and stabilization of the allograft injury. This case highlights the potential of interleukin-6 blockade as a treatment for refractory chronic active antibody-mediated rejection, particularly in the context of interleukin-6-mediated injury.
Insights
Tocilizumab, an interleukin-6 (IL-6) receptor monoclonal antibody, shows promise for treating chronic active antibody-mediated rejection in kidney transplant patients. This approach may be particularly effective when IL-6 levels are elevated, improving graft function.
Area of Science:
- Nephrology
- Immunology
- Transplantation
Background:
- End-stage renal disease (ESRD) due to diabetes and hypertension often necessitates kidney transplantation.
- Chronic active antibody-mediated rejection (CAAMR) is a significant cause of renal allograft failure.
- Standard treatments for CAAMR, including immunotherapy, are not always effective.
Purpose of the Study:
- To report a case of refractory CAAMR following renal transplantation.
- To investigate the efficacy of IL-6 blockade in a patient with elevated IL-6 levels and CAAMR.
- To highlight a potential novel therapeutic strategy for difficult-to-treat CAAMR.
Main Methods:
- A patient with ESRD, diabetes, and hypertension received a renal transplant.
- The patient developed refractory CAAMR despite standard immunosuppressive therapy.
- Treatment with tocilizumab, an IL-6 receptor antagonist, was initiated due to elevated IL-6 levels.
Main Results:
- Tocilizumab treatment led to a significant decrease in serum creatinine levels.
- Renal allograft injury stabilized following tocilizumab administration.
- Persistent donor-specific antibodies were noted, but graft function improved.
Conclusions:
- Interleukin-6 (IL-6) blockade with tocilizumab may be a viable treatment option for refractory CAAMR.
- This approach is particularly relevant in cases where IL-6-mediated injury is suspected.
- Targeting IL-6 offers a potential new avenue for managing challenging kidney transplant rejection scenarios.
More Related Videos
Related Concept Videos
Hypothesis: Accept or Fail to Reject?
There are two ways to indicate that the null hypothesis is not rejected. 'Accept' the null...
Standards of Care II
Standards of Care I
Patient-centered Care
Acute Kidney Injury V: Interprofessional Care
Counterfactual Thinking

